Tae You Kim1, Chia-Jui Yen2, Salah-Eddin Al-Batran3, David Ferry4, Ling Gao4, Yanzhi Hsu4, Rebecca Cheng5, Mauro Orlando6, Atsushi Ohtsu7. 1. Seoul National University Cancer Hospital, Seoul, South Korea. 2. Division of Hematology and Oncology, Department of Internal Medicine, Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. 3. Institute of Clinical Cancer Research (IKF), UCT-University Cancer Center, Frankfurt, Germany. 4. Eli Lilly and Company, Bridgewater, NJ, USA. 5. Eli Lilly and Company, Taipei, Taiwan. 6. Eli Lilly and Company, Buenos Aires, Argentina. 7. National Cancer Center, Hospital East, Kashiwa, Japan. aohtsu@east.ncc.go.jp.
Abstract
BACKGROUND:Ramucirumab is a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor-2. Second-line ramucirumab, in conjunction with paclitaxel (ramucirumab 8 mg/kg or placebo in combination with 80 mg/m2 paclitaxel), has been shown to be effective and safe in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in RAINBOW, a global phase III randomized clinical trial. We conducted an exploratory exposure-response analysis of efficacy and safety of ramucirumab in East Asian patients from the RAINBOW trial. METHODS: Using sparse pharmacokinetic samples collected in the RAINBOW trial, a population pharmacokinetic analysis was conducted to predict ramucirumab minimum trough concentration at steady state (C min,ss) using a nonlinear mixed-effect modeling approach. Kaplan-Meier and Cox proportional hazards analyses were conducted to evaluate ramucirumab exposure (C min,ss) and efficacy relationship by overall survival and progression-free survival. Exposure-safety relationships were assessed descriptively. RESULTS:Two hundred and twenty-two East Asian patients were included in this exposure-response analysis. Higher ramucirumab C min,ss was associated with longer overall survival (p = 0.0115) and progression-free survival (p = 0.0179) in this patient cohort. Patients with higher ramucirumab C min,ss (≥56.87 ng/ml median) had higher incidences of grade ≥3 leukopenia and neutropenia, but not febrile neutropenia or hypertension. CONCLUSIONS: This exploratory analysis suggests a positive relationship between efficacy and ramucirumab exposure with manageable toxicities in East Asian patients from RAINBOW, consistent with the overall exposure-response analysis from this trial. A regimen with a higher dosage of ramucirumab warrants further consideration for East Asian patients with gastric/GEJ cancer.
RCT Entities:
BACKGROUND:Ramucirumab is a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor-2. Second-line ramucirumab, in conjunction with paclitaxel (ramucirumab 8 mg/kg or placebo in combination with 80 mg/m2 paclitaxel), has been shown to be effective and safe in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in RAINBOW, a global phase III randomized clinical trial. We conducted an exploratory exposure-response analysis of efficacy and safety of ramucirumab in East Asian patients from the RAINBOW trial. METHODS: Using sparse pharmacokinetic samples collected in the RAINBOW trial, a population pharmacokinetic analysis was conducted to predict ramucirumab minimum trough concentration at steady state (C min,ss) using a nonlinear mixed-effect modeling approach. Kaplan-Meier and Cox proportional hazards analyses were conducted to evaluate ramucirumab exposure (C min,ss) and efficacy relationship by overall survival and progression-free survival. Exposure-safety relationships were assessed descriptively. RESULTS: Two hundred and twenty-two East Asian patients were included in this exposure-response analysis. Higher ramucirumab C min,ss was associated with longer overall survival (p = 0.0115) and progression-free survival (p = 0.0179) in this patient cohort. Patients with higher ramucirumab C min,ss (≥56.87 ng/ml median) had higher incidences of grade ≥3 leukopenia and neutropenia, but not febrile neutropenia or hypertension. CONCLUSIONS: This exploratory analysis suggests a positive relationship between efficacy and ramucirumab exposure with manageable toxicities in East Asian patients from RAINBOW, consistent with the overall exposure-response analysis from this trial. A regimen with a higher dosage of ramucirumab warrants further consideration for East Asian patients with gastric/GEJ cancer.
Entities:
Keywords:
East Asian patients; Exposure response; Gastric cancer; Ramucirumab; Vascular endothelial growth factor receptor-2
Authors: Hui Cai; Fei Ye; Angelika Michel; Gwen Murphy; Shizuka Sasazuki; Philip R Taylor; You-Lin Qiao; Sue K Park; Keun-Young Yoo; Sun Ha Jee; Eo Rin Cho; Jeongseon Kim; Sheau-Chiann Chen; Christian C Abnet; Shoichiro Tsugane; Qiuyin Cai; Xiao-Ou Shu; Wei Zheng; Michael Pawlita; Meira Epplein Journal: Int J Epidemiol Date: 2016-05-11 Impact factor: 7.196
Authors: Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero Journal: Lancet Date: 2013-10-03 Impact factor: 79.321
Authors: Tianyi Wang; Hui Cai; Shizuka Sasazuki; Shoichiro Tsugane; Wei Zheng; Eo Rin Cho; Sun Ha Jee; Angelika Michel; Michael Pawlita; Yong-Bing Xiang; Yu-Tang Gao; Xiao-Ou Shu; Wei-Cheng You; Meira Epplein Journal: Int J Cancer Date: 2016-10-31 Impact factor: 7.396
Authors: Jennifer L Spratlin; Roger B Cohen; Matthew Eadens; Lia Gore; D Ross Camidge; Sami Diab; Stephen Leong; Cindy O'Bryant; Laura Q M Chow; Natalie J Serkova; Neal J Meropol; Nancy L Lewis; E Gabriela Chiorean; Floyd Fox; Hagop Youssoufian; Eric K Rowinsky; S Gail Eckhardt Journal: J Clin Oncol Date: 2010-01-04 Impact factor: 44.544
Authors: Hye Sook Han; Bum Jun Kim; Hee-Jung Jee; Min-Hee Ryu; Se Hoon Park; Sun Young Rha; Jong Gwang Kim; Woo Kyun Bae; Keun-Wook Lee; Do-Youn Oh; In-Ho Kim; Sun Jin Sym; So Yeon Oh; Hyeong Su Kim; Ji-Hye Byun; Dong Sook Kim; Young Ju Suh; Hyonggin An; Dae Young Zang Journal: Ther Adv Med Oncol Date: 2021-09-18 Impact factor: 8.168